| Literature DB >> 30886048 |
Eva M van Well1, Verian Bader1, Maria Patra2, Ana Sánchez-Vicente1, Jens Meschede1, Nikolas Furthmann1, Cathrin Schnack1, Alina Blusch3, Joseph Longworth4, Elisabeth Petrasch-Parwez5, Kohji Mori6, Thomas Arzberger7,8,9, Dietrich Trümbach10, Lena Angersbach1, Cathrin Showkat1, Dominik A Sehr1, Lena A Berlemann1, Petra Goldmann1, Albrecht M Clement11, Christian Behl11, Andreas C Woerner12, Carsten Saft3, Wolfgang Wurst9,10,13,14, Christian Haass6,9,14, Gisa Ellrichmann3, Ralf Gold3, Gunnar Dittmar4, Mark S Hipp12,14, F Ulrich Hartl12,14, Jörg Tatzelt2,15,16, Konstanze F Winklhofer17,2,9,14,16.
Abstract
Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain. Insights into protein quality control mechanisms to prevent neuronal dysfunction and cell death are crucial in developing causal therapies. Here, we report that various disease-associated protein aggregates are modified by the linear ubiquitin chain assembly complex (LUBAC). HOIP, the catalytic component of LUBAC, is recruited to misfolded Huntingtin in a p97/VCP-dependent manner, resulting in the assembly of linear polyubiquitin. As a consequence, the interactive surface of misfolded Huntingtin species is shielded from unwanted interactions, for example with the low complexity sequence domain-containing transcription factor Sp1, and proteasomal degradation of misfolded Huntingtin is facilitated. Notably, all three core LUBAC components are transcriptionally regulated by Sp1, linking defective LUBAC expression to Huntington's disease. In support of a protective activity of linear ubiquitination, silencing of OTULIN, a deubiquitinase with unique specificity for linear polyubiquitin, decreases proteotoxicity, whereas silencing of HOIP has the opposite effect. These findings identify linear ubiquitination as a protein quality control mechanism and hence a novel target for disease-modifying strategies in proteinopathies.Entities:
Keywords: zzm321990LUBACzzm321990; zzm321990OTULINzzm321990; Huntingtin; p97; protein aggregation
Mesh:
Substances:
Year: 2019 PMID: 30886048 PMCID: PMC6484417 DOI: 10.15252/embj.2018100730
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598